Skip to main content

Table 9 Full name of interventions belonged to objective four and Fig. 4

From: Assessment and prioritization of the WHO “best buys” and other recommended interventions for the prevention and control of non-communicable diseases in Iran

CodeFull name of the interventions that prioritized in Fig. 4
4.9Drug therapy (including glycaemic control for diabetes mellitus and control of hypertension using a total risk* approach) and counseling to individuals who have had a heart attack or stroke and to persons with high risk (≥ 30%) of a fatal and non-fatal cardiovascular event in the next 10 years
4.10Treatment of new cases of acute myocardial infarction** with either: acetylsalicylic acid, or acetylsalicylic acid and clopidogrel, or thrombolysis, or primary percutaneous coronary interventions (PCI)
4.11Treatment of acute ischemic stroke with intravenous thrombolytic therapy
4.15Cardiac rehabilitation post-myocardial infarction
4.16Anticoagulation for medium-and high-risk non-valvular atrial fibrillation and for mitral stenosis with atrial fibrillation
4.14Treatment of congestive cardiac failure with angiotensin-converting-enzyme inhibitor, beta-blocker, and diuretic
4.13Secondary prevention of rheumatic fever and rheumatic heart disease by developing a register of patients who receive regular prophylactic penicillin
4.12Primary prevention of rheumatic fever and rheumatic heart diseases by increasing appropriate treatment of streptococcal pharyngitis at the primary care level
4.17Low-dose acetylsalicylic acid for ischemic stroke
4.18Care of acute stroke and rehabilitation in stroke units
4.27Prevention of cervical cancer by screening women aged 30–49 years
4.26Vaccination against human papillomavirus (2 doses) of 9–13-year-old girls
4.28Screening with mammography (once every 2 years for women aged 50–69 years) linked with timely diagnosis and treatment of breast cancer
4.29Treatment of colorectal cancer stages I and II with surgery +/− chemotherapy and radiotherapy
4.34Symptom relief for patients with chronic obstructive pulmonary disease with inhaled salbutamol
4.19Preventive foot care for people with diabetes (including educational programs, access to appropriate footwear, multidisciplinary clinics
4.21Effective glycaemic control for people with diabetes, along with standard home glucose monitoring for people treated with insulin to reduce diabetes complications
4.20Diabetic retinopathy screening for all diabetes patients and laser photocoagulation for prevention of blindness
4.33Symptom relief for patients with asthma with inhaled salbutamol
4.35Treatment of asthma using low dose inhaled beclometasone and short-acting beta-agonist
4.32Population-based colorectal cancer screening, including through a faecal occult blood test, as appropriate, at age > 50 years, linked with timely treatment
4.31Oral cancer screening in high-risk groups (for example, tobacco users, betel-nutchewers) linked with timely treatment
4.30Prevention of liver cancer through hepatitis B immunization
4.25Screening of people with diabetes for proteinuria and treatment with angiotensin-converting enzyme inhibitor for the prevention and delay of renal disease
4.37Cost-effective interventions to prevent occupational lung diseases, for example, from exposure to silica, asbestos
4.38Influenza vaccination for patients with chronic obstructive pulmonary disease
4.23Influenza vaccination for patients with diabetes
4.22Lifestyle interventions for preventing type 2 diabetes
4.24Preconception care among women of reproductive age who have diabetes including patient education and intensive glucose management
4.36Access to improved stoves and cleaner fuels to reduce indoor air pollution